This hypothesis emphasizes the need to understand the“fate” of the LAP after pathophysiologic activation ofTGF-β1 and may support investigating it as a novel biological target forfibrotic and inflammatory human disease. Here, TGFB1 is linked to glycogen storage disease VI.